CJC-1295 with DAC vs LL-37
Well Studied vs Well Studied
synergistic Mechanism-based · 47% CJC-1295 with DAC and LL-37 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 with DAC LL-37
Weight 3,647.28 Da —
Half-life 6-8 days Short (rapid proteolytic degradation)
Chain 30 amino acids 37 amino acids
Type GHRH analog with DAC Cationic antimicrobial peptide
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
LL-37
01 Direct wound healing acceleration
02 Broad-spectrum antimicrobial activity
03 Activity against resistant bacteria (MRSA, MDRPA)
04 Enhanced tissue regeneration
05 Immune modulation
06 Local antimicrobial protection
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
LL-37
0.5-1.6 mg/mL topical gel or 100-150 mcg injectable / Topical: Daily to twice weekly on wounds. Injectable: Once daily subcutaneous
Systemic immune support 100-150mcg Once daily
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
LL-37
Generally well-tolerated
Mild injection site reactions (injectable)
Local irritation at application site (topical)
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Pre-existing hypersensitivity to peptides
Compromised immune status (relative contraindication)
Non-sterile wound environments
Research Evidence
CJC-1295 with DAC LL-37
Status Well Studied Well Studied
References 4 studies 4 studies
Latest 2025 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.